Protalix BioTherapeutics found using ticker (PLX) have now 2 analysts in total covering the stock. The consensus rating is ‘Buy’. The target price ranges between 15 and 11 calculating the mean target price we have 13. With the stocks previous close at 5.14 this now indicates there is a potential upside of 152.9%. The day 50 moving average is 4.85 and the 200 day MA is 4.11. The market cap for the company is $233m. Find out more information at: http://www.protalix.com
Protalix BioTherapeutics, a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, rest of Latin America, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; FundaÃ§Ã£o Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is headquartered in Karmiel, Israel.